ARC advises patients regarding new FDA recommendations for sleeping pills containing zolpidemJanuary 11, 2013
The U.S. Food and Drug Administration (FDA) is recommending lowering the maximum dosage of sleeping pills containing zolpidem, or the brand name Ambien, in its regular and extended release form, especially as prescribed for women. The recommendation was made to help women avoid excessive daytime sedation that could affect alertness and ability to drive.
If you are currently taking a dosage of more than 5 mg in regular-release form, or 6.25 in extended-release form of zolpidem/Ambien, please do not discontinue taking your medicine before consulting with your physician. ARC physicians will be happy to discuss risks and alternatives at your appointment.
For more information, visit U.S. Food and Drug Adminstration (FDA) website.